Catabasis Pharma (CATB) Tops Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Catabasis (CATB) PT Lowered to $9 at Oppenheimer; Reiterates Outperform
May 12, 2017 9:25 AM EDTOppenheimer lowered its price target on Catabasis (NASDAQ: CATB) to $9.00 (from $11.00) while maintaining a Outperform rating. Catabasis reported earnings on May 11, with OPEX coming in 10% below OPCO expectations.
Analyst Hartaj Singh updated OPEX estimates to reflect a smaller OPEX... More
